PTC Therapeutics PTCT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $833.99M-15.3% | $984.65M+46.4% | $672.62M-33.9% | $1.02B-31.3% | $1.48B+89.8% | ||
| $1.06B+10.2% | $960.72M-5.4% | $1.02B+4.5% | $971.76M+77.7% | $546.95M+51.9% | ||
| $219.92M+21.1% | $181.62M-10.6% | $203.07M+3.5% | $196.13M-6.8% | $210.5M+32.8% | ||
| $75.57M-5.1% | $79.65M+51.2% | $52.69M+54.7% | $34.06M+57.1% | $21.68M-6.5% | ||
| $66.05M-1.9% | $67.31M+4.8% | $64.22M+20.0% | $53.53M-6.2% | $57.06M+29.4% | ||
| $2.25B-0.9% | $2.27B+13.3% | $2.01B-11.7% | $2.27B-1.9% | $2.32B+69.6% | ||
| $52.74M-4.8% | $55.37M-2.8% | $56.97M-0.4% | $57.19M-3.8% | $59.46M-2.5% | ||
| $76.69M-4.2% | $80.05M-0.8% | $80.68M+43.7% | $56.16M-2.0% | $57.32M+1.1% | ||
| $82.34M0.0% | $82.34M0.0% | $82.34M0.0% | $82.34M0.0% | $82.34M0.0% | ||
| $380.68M-2.1% | $388.75M-1.9% | $396.47M+176% | $143.81M+21.4% | $118.45M-0.3% | ||
| -$10K— | —— | —— | —— | $2K+100% | ||
| $2.87B-1.0% | $2.9B+9.6% | $2.64B+0.4% | $2.63B-0.8% | $2.66B+55.7% | ||
| $313.05M-17.9% | $381.27M+25.8% | $303.14M-10.6% | $338.95M+6.7% | $317.81M+4.4% | ||
| $498K-75.6% | $2.04M+20.6% | $1.69M-82.7% | $9.76M-23.9% | $12.83M+133% | ||
| $286.94M+0.1% | $286.63M+0.1% | $286.32M+5,244% | $5.36M+6.2% | $5.05M+68.2% | ||
| $12.08M-3.3% | $12.48M+5.7% | $11.81M+0.7% | $11.73M+2.3% | $11.46M+10.6% | ||
| $6M+100% | $3M+12.1% | $2.68M-50.1% | $5.36M+6.2% | $5.05M+68.2% | ||
| $923.6M-4.6% | $968.43M+11.8% | $866.25M+38.0% | $627.81M+5.4% | $595.39M+2.5% | ||
| $90.07M-3.8% | $93.58M-2.0% | $95.49M+34.0% | $71.24M-3.2% | $73.56M-1.9% | ||
| —— | $3M-78.3% | $13.83M0.0% | $13.83M0.0% | $13.83M-11.2% | ||
| $13.7M0.0% | $13.7M+431% | $2.58M-67.0% | $7.82M-65.1% | $22.43M+4.7% | ||
| $3.05B-1.8% | $3.1B+10.9% | $2.8B-1.5% | $2.84B0.0% | $2.84B+1.4% | ||
| $81K+1.3% | $80K+1.3% | $79K+1.3% | $78K0.0% | $78K+1.3% | ||
| $2.78B+1.1% | $2.75B+3.0% | $2.67B+1.4% | $2.63B+0.9% | $2.61B+1.3% | ||
| -$2.97B-0.1% | -$2.96B-4.8% | -$2.83B+0.6% | -$2.85B-2.3% | -$2.78B+23.8% | ||
| $8.47M-19.4% | $10.5M+77.1% | $5.93M-19.4% | $7.36M+153% | -$13.95M+46.1% | ||
| -$180.47M+12.1% | -$205.31M-31.8% | -$155.76M+24.6% | -$206.55M-11.2% | -$185.76M+83.1% | ||
| $2.87B-1.0% | $2.9B+9.6% | $2.64B+0.4% | $2.63B-0.8% | $2.66B+55.7% | ||
| $1.06B+10.2% | $960.72M-5.4% | $1.02B+4.5% | $971.76M+77.7% | $546.95M+51.9% | ||
| $76.69M-4.2% | $80.05M-0.8% | $80.68M+43.7% | $56.16M-2.0% | $57.32M+1.1% | ||
| $22.65M+23.7% | $18.3M-5.8% | $19.44M-10.8% | $21.78M+1.7% | $21.42M+3.4% | ||
| $380.68M-2.1% | $388.75M-1.9% | $396.47M+176% | $143.81M+21.4% | $118.45M-0.3% | ||
| $76.69M-4.2% | $80.05M-0.8% | $80.68M+43.7% | $56.16M-2.0% | $57.32M+1.1% | ||
| $76.69M-4.2% | $80.05M-0.8% | $80.68M+43.7% | $56.16M-2.0% | $57.32M+1.1% | ||
| $313.05M-17.9% | $381.27M+25.8% | $303.14M-10.6% | $338.95M+6.7% | $317.81M+4.4% | ||
| $305.04M+7.8% | $283M+8.6% | $260.61M-0.5% | $262.02M+5.6% | $248.24M-3.7% | ||
| $395.09M-0.9% | $398.7M-2.8% | $410.13M+4.2% | $393.52M-0.3% | $394.66M+0.6% | ||
| $81K+1.3% | $80K+1.3% | $79K+1.3% | $78K0.0% | $78K+1.3% | ||
| $6M+100% | $3M+12.1% | $2.68M-50.1% | $5.36M+6.2% | $5.05M+68.2% | ||
| $2.02B-0.2% | $2.03B+11.2% | $1.82B-0.7% | $1.83B-0.9% | $1.85B+1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are PTC Therapeutics's total assets?
- PTC Therapeutics (PTCT) holds $2.9B in total assets, up 8.1% year over year.
- How much debt does PTC Therapeutics have?
- PTC Therapeutics carries $395.1M in total debt against -$180.5M of shareholders' equity, a debt-to-equity ratio of 372.31.
- How much cash does PTC Therapeutics have?
- PTC Therapeutics holds $834.0M in cash and equivalents.
- Can PTC Therapeutics cover its short-term obligations?
- Its current ratio is 2.44 — current assets exceed current liabilities.
- Where does PTC Therapeutics's balance sheet data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
